1 / 33

Australasian Society of Clinical Immunology and Allergy Adverse Reactions to NSAIDs

Australasian Society of Clinical Immunology and Allergy Adverse Reactions to NSAIDs. David Henry Faculty of Medicine and Health Sciences The University of Newcastle NSW Australia. Aims of this presentation.

wanda
Download Presentation

Australasian Society of Clinical Immunology and Allergy Adverse Reactions to NSAIDs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Australasian Society of Clinical Immunology and AllergyAdverse Reactions to NSAIDs David Henry Faculty of Medicine and Health Sciences The University of Newcastle NSW Australia

  2. Aims of this presentation • To show how epidemiological methods can be used to investigate adverse drug effects • To review the main ‘predictable’ adverse effects of NSAIDs on the GI tract kidneys and cardiovascular system • To discuss how such data can be used in health services research to influence practice and policy

  3. Background • Non steroidal anti-inflammatory drugs (NSAIDs) are widely used for management of a range of painful disorders • NSAIDs are the commonest reported cause of serious adverse reactions to drugs • NSAIDs can cause serious ADRs in any body system, but those involving the upper GIT the CVS and the kidneys are the most common • The outcomes of these ADRs are hemorrhage, ulcer perforation, renal failure, heart failure

  4. Questions that need to be addressed • How frequently are these drugs used? • What are the levels of risk of development of serious GIH, functional renal impairment, congestive heart failure? • To what extent are these risks dependent on factors such as drug dose, half-life, COX selectivity?

  5. Questions that need to be addressed (cont) • What are the associated public heath burdens? • What are the practice and policy implications?

  6. How commonly are these drugs used? • Prescription survey : In 1988 12 million prescriptions were written for NSAIDs in Australia • Prevalence survey: In 1987/88 23% of women and 20% of men aged >65 years in Newcastle had taken NSAIDs in the previous 4 days (not including aspirin). This figure dropped to around 15% by 1994

  7. What are the levels of risk for development of serious gastrointestinal hemorrhage and ulcer perforation, and what factors modify this risk?

  8. Principal Methodology:Case-control Study • Major advantages over traditional case series • Involves definition and careful selection of • subjects with the disease (cases) • subjects without the disease (controls) • Unbiased measurement of prior use of the drugs of interest

  9. Principal Methodology:Case-control Study • The Odds Ratio (adjusted for confounders ) provides an estimate of the Relative Risk of the outcome in exposed compared with non-exposed individuals • The Odds Ratio is an accurate estimate of the Relative Risk when the condition under study is uncommon

  10. Relative Risk • Background Risk 1/1000 • Relative Risk 4.0 • Risk in exposed group 4/1000 • Excess risk 3/1000

  11. Major gastrointestinal complications • Case-control study to determine the risk of development of GI complications • Case-control study to determine the risk of dying of GI complications • Collaborative meta-analysis to determine the variation in risk with individual compounds

  12. Major gastrointestinal complications (cont) • Information on 644 cases of GIH or ulcer perforation and 1268 community and hospital controls (matched for age and sex) • Overall Relative Risk 3.0(2.3, 3.5) • Dose response relationship obvious • Apparent differences in risk between individual drugs

  13. Death from major GI complications • Information on 80 cases who died of peptic ulcer complications and 160 controls who survived hospitalisation with peptic ulcer complications • Controls were matched on age, sex, site and nature of complication and analyses were adjusted for co-morbidity • Adjusted RR of dying of peptic ulcer complications with use of NSAIDs or aspirin were 1.1 (0.6, 2.1) and 1.2 (0.5, 1.9) respectively

  14. Collaborative Meta-analysis • Investigators from six countries pooled data from 12 epidemiological studies with data from 10,000 cases and 30,000 controls • The main aim was to investigate the range of risks with individual agents and the extent to which this could be explained by dosage • Results were combined by ranking as different combinations of drugs had been included in different studies

  15. Estimated relative risks of major gastrointestinal complications with individual drugs Estimated relative risk 50 5 0.5 Aza Pirox Keto Indo Nap Asp Sulin Difl Dicl Ibup .

  16. Estimated relative risks of major gastrointestinal Estimated relative risks of major gastrointestinal complications with individual drugs complications with individual drugs Summary ranking method Summary ranking method Ibup n=11 Dicl n=9 Difl n=2 Fenop n=2 Asp n=6 Sulin n=5 Nap n=12 Indo n=12 Pirox n=11 Ketop n=7 Tolm n=2 Aza n=2 0 2 4 6 8 10 12 14 Rank from low risk to high risk: avge of 12 top scores

  17. Major gastrointestinal complications : Conclusions • Overall RR around 3.0. Higher for perforation • Case-fatality rate unaffected by NSAIDs • 34% of elderly bleeds due to NSAIDs • Significant differences between individual drugs: ibuprofen and diclofenac have the lowest risks and piroxicam and ketoprofen the highest

  18. Cardiac and Renal Complications • Vasodilator PGs are important in maintaining renal blood flow, and (possibly) modulating systemic vascular resistance in times of stress • NSAIDs have been shown to reduce GFR and increase systemic vascular resistance in selected individuals • There have been very few epidemiological studies and these have been confined to end-stage renal failure

  19. Cardiac and Renal Complications • Case-control study of 365 cases of CHF and 658 matched controls • Case-control study of 110 cases of functional renal impairment (FRI) and 189 matched controls • The estimated RR for hospitalisation with first episode of CHF with NSAIDs was 2.8 (1.5, 5.1). Etiologic fraction 19% • The estimated RR for hospitalisation with evidence of FRI with NSAIDs was 1.5 (0.80, 2.9).

  20. How do we study factors such as drug dose, half-life and COX selectivity in epidemiological studies of NSAID toxicity?

  21. Effects of Dose on Relative Risk of GI Complications with Individual NSAIDs: meta-analysis RR, 95% CI 10 8 6 4 2 0 Low High Low High Low High Ibuprofen Naproxen Indomethacin

  22. Effects of Dose on Relative Risk of CHF

  23. The Relationship between GI Risk and Drug Half-life • Relative risks were ordered by the summary ranking procedure (meta-analysis) • Published values for T1/2 were ranked • Non parametric correlation: • Kendall’s Tau 0.504, P = 0.023

  24. The Relationship between Half-life and risk of CHF • Relationship between T1/2 and RR for first admission with CHF (multivariate): • <4 hrs 2.0 (0.56, 7.4) • 5 - 11 hrs 4.3 (0.66, 27.4) • > 12 hrs 10.6 (1.1, 103.7) • P (for trend) = 0.016

  25. The Relationship between Half-life and risk of Renal Impairment • Relationship between T1/2 and RR for functional renal impairment (multivariate): • <4 hrs 1.3 (0.48, 3.6) • 5 - 11 hrs 2.8 (0.66, 12.0) • > 12 hrs 3.8 (0.68, 21.0) • P (for trend) = 0.012

  26. COX selectivity • Cyclo-oxygenase exists in two isoforms, COX-1 and COX-2 • COX-1 is responsible for the ‘constitutional’ effects of PGs • COX-2 is responsible for the inflammatory effects

  27. COX selectivity • Drugs were ranked by COX-1, COX-2 activities and COX-1/COX-2 ratio • Relative risks were ordered by the summary ranking procedure (meta-analysis) • Significant correlation with COX-1 activity, but not with the other variables

  28. Public Health Issues • GI complications: 4000 - 5000 admissions in elderly subjects annually, and 300 - 400 deaths • Approximately 1500 admissions and 100 deaths are attributable to use of NSAIDs • Cardiac Failure: 50,000+ admissions annually, with 5000 deaths in hospital and many more in the next year • Approximately 8000 admissions and up to 800 deaths could be attributable to use of NSAIDs

  29. What is happening to use of NSAIDs in Australia ?

  30. Recent Trends in Use of NSAIDsMcManus et al MJA 1996; 164: 589-592 • Overall use of NSAIDs fell from 50.1 DDD/1000/day in 1990 to 34.6 DDD/1000/day in 1994 (31% fall) • In subjects over 60 years prescription use fell by 44%

  31. Recent Trends in Use of NSAIDsMcManus et al MJA 1996; 164: 589-592 • The fall in the use of ‘low risk’ drugs (ibuprofen, diclofenac and diflunisal) was greater than the fall in ‘high risk’ drugs (piroxicam and ketoprofen)

  32. Selection of NSAIDs by GPs • Analysis of NSAID prescribing by 2 GP Divisions with similar overall rates (per 100 MC services) • Feedback of data may result in an overall reduction in prescribing and a shift to the left

  33. Conclusions • The high use of NSAIDs constitutes a problem of public health dimensions • The cardiovascular effects are little recognised and in community terms may be more important than the GI effects • There are significant differences in risk between the drugs. Both dose and drug half-life seem important • COX-selectivity potentially is an important factor but assessment with current data difficult due to confounding

More Related